Re: Hepalink
in response to
by
posted on
Feb 21, 2020 10:13AM
Seeing that "MACE can include both atherosclerotic events (MI and stroke) and CHF events," what's to prevent Hepalink from manufacturing Apabetalone in compliance with their licence agreement with Resverlogix?
Koo